You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):聘任劉勇軍擔任執行總裁和全球研發總裁
格隆匯 09-09 12:03

格隆匯9月9日丨石藥集團(01093.HK)宣佈,已聘任劉勇軍擔任集團執行總裁和全球研發總裁,負責集團研發、管線戰略及國際業務開拓等工作。

劉勇軍深耕生物醫藥行業超過30年,是免疫學、腫瘤學以及轉化醫學領域全球知名的科學家,曾任職信達生物、賽諾菲、阿斯利康(MedImmune)等多家公司的研發負責人,在國際着名科研機構和全球頂尖製藥企業研發部門擁有豐富的工作經驗。

此外,劉勇軍擁有豐富的科研成果和經驗,他在Nature和Science等頂尖學術期刊共發表了超過260篇論文,總引用次數超過94,000次。這些研究為免疫學和腫瘤學領域提供了多個關鍵的藥物靶點,如胸腺基質淋巴生成素(TSLP)、OX40(CD134)、漿細胞樣樹突細胞(pDCs)等,推動了多個領域的臨牀前研究,使得許多候選藥物從最初的實驗室發現走向臨牀。

劉勇軍於中國白求恩醫科大學取得醫學學士學位,並於英國伯明翰大學取得免疫學博士學位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account